Cite
HARVARD Citation
Zhou, Q. et al. (2022). Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet oncology. 23 (2), pp. 209-219. [Online].